DWP820S011

DWP820S011 is an experimental gene therapy candidate currently in preclinical development by Daewoong Pharmaceutical for the treatment of retinitis pigmentosa (RP). Retinitis pigmentosa is a group of rare genetic disorders characterized by the progressive degeneration of photoreceptor cells in the retina, leading to severe vision loss and potential blindness. DWP820S011 is designed to address the underlying pathology of the disease by delivering therapeutic genetic material to the retinal cells, typically utilizing a viral vector such as an adeno-associated virus (AAV). The program aims to provide a mutation-independent or targeted approach to preserve retinal function and prevent further cell death in patients suffering from this debilitating condition.